Grant of share options

RNS Number : 8069X

IXICO plc

10 January 2022

 

IXICO plc

("IXICO" or the "Company")

Grant of share options

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that it has granted 300,000 options over the ordinary shares in the Company in accordance with the rules of the Company's EMI Share Option Plan 2014 (the 'Plan') exercisable at a share price of 1p.

These options are subject to performance conditions linked to compound share price growth across three years.  Robin Wolz, Chief Scientific Officer, Romina Oxborough, SVP Operations and Chris Hamilton, SVP Commercial who are all considered PDMRs as members of the IXICO Senior Leadership Team, each receive 100,000 options under this award.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Robin Wolz
2	Reason for the notification
a)	Position/status	Chief Scientific Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	IXICO plc
b)	LEI	2138005M1F59O6HWSA97
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares in IXICO plc
	Identification code	GB00BCLY7L40
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1p	100,000
d)	Aggregated information	N/A
	- Aggregated volume
	- Price
e)	Date of the transaction	10 January 2022
f)	Place of the transaction	Off market

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Romina Oxborough
2	Reason for the notification
a)	Position/status	PDMR (SVP Operations)
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	IXICO plc
b)	LEI	2138005M1F59O6HWSA97
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares in IXICO plc
	Identification code	GB00BCLY7L40
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1p	100,000
d)	Aggregated information
	- Aggregated volume	N/A
	- Price
e)	Date of the transaction	10 January 2022
f)	Place of the transaction	Off market

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Chris Hamilton
2	Reason for the notification
a)	Position/status	PDMR (SVP Commercial)
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	IXICO plc
b)	LEI	2138005M1F59O6HWSA97
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares in IXICO plc
	Identification code	GB00BCLY7L40
b)	Nature of the transaction	Grant of share options
c)	Price(s) and volume(s)
			Price(s)	Volume(s)
			1p	100,000
d)	Aggregated information	N/A
	- Aggregated volume
	- Price
e)	Date of the transaction	10 January 2022
f)	Place of the transaction	Off market

For further information please contact:

IXICO plc			[phone]
Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer
Cenkos Securities PLC (Nominated adviser and sole broker)				[phone]
Giles Balleny / Max Gould (Corporate Finance)
Michael F Johnson / Russell Kerr (Sales)
Walbrook PR Ltd	Tel: [phone] or [e-mail]
Paul McManus / Lianne Applegarth /		Mob: [phone] /
Alice Woodings		07407 804 654

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience and our goal is to be a leading proponent of artificial intelligence in medical image analysis. We will achieve this by developing and deploying breakthrough data analytics, at scale, through our remote access technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for our pharmaceutical clients.

More information is available on www.IXICO.com   and follow us on Twitter @IXICOnews

 

END

 

 

DSHUBRURUOUARAR